Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$9.1B
1,047M shares
52-week range
$1.95 – $12.43
65% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
3.23%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47.0K | $43.0K | $605.0K | $934.0K | $240.0K | $622.0K | $14.7M | $113.3M |
| Cost of revenue | −$3.1M | $9.0M | $0 | $0 | $0 | $0 | $0 | $753.0K |
| Gross profit | $3.2M | −$9.0M | $605.0K | $934.0K | $240.0K | $622.0K | $14.7M | $112.5M |
| Gross margin | 6717.0% | -20858.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.3% |
| R&D | $53.4M | $48.9M | $139.5M | $196.0M | $248.1M | $232.4M | $190.1M | $207.9M |
| Operating income | −$98.4M | −$66.9M | −$220.9M | −$330.3M | −$351.3M | −$362.3M | −$344.2M | −$256.0M |
| EBITDA | −$86.7M | −$56.9M | −$204.2M | −$320.8M | −$351.9M | −$478.7M | −$264.4M | −$223.6M |
| Net income | −$96.2M | −$65.8M | −$221.9M | −$346.8M | −$416.6M | −$583.2M | −$413.6M | −$351.4M |
| Net margin | -204736.2% | -152997.7% | -36669.6% | -37129.6% | -173569.6% | -93761.4% | -2804.8% | -310.2% |
| EPS (diluted) | -0.30 | -0.42 | -0.59 | -0.89 | -1.04 | -1.15 | -0.62 | -0.38 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $222M | $-0.85 | $-0.88–$-0.81 | 2 |
| 2027 | $452M | $-0.16 | $-0.38–$0.07 | 2 |
| 2028 | $1.4B | $0.54 | $0.31–$0.84 | 1 |
| 2029 | $2.3B | $0.95 | $0.55–$1.47 | 1 |
Forward consensus · source: Financial Modeling Prep
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
www.immunitybio.comNo one on the platform currently holds IBRX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 1,231,770 | $2.4M |
No one on the platform has traded IBRX yet.
| $4.1B |
| — |
| ETNB89bio, Inc. | $14.84 | +0.00% | $2.2B | — |
| GLPGGalapagos N.V. | $27.98 | +1.71% | $1.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
$SLS We are moving up ! along with $IBRX https://stocktwits.com/news-articles/markets/equity/sls-ibrx-xbi-analyst-continued-opportunities-immuno-oncology/cZ1BDwKR7hT
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Trading at 192.0× sales vs its 2264.2× historical median P/S.
Fair value ≈ $102.91 · price $8.72 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.